Sumitomo Chemical Co., Ltd.

Sumitomo Chemical Co., Ltd.

500.50
JPY
-6.40
(-1.26%)
78.87EPS
9.19P/E
947.58BMarket Cap
Feb 03Next Earn

Q2 FY2027 · Earnings Call TranscriptNovember 2, 2026

Operator

It is now the scheduled time to start, we would like to start the conference call regarding the financial results for fiscal year 2026 second quarter. Thank you for your participation.

Today, Yamauchi, Managing Executive Officer, will explain the financial results for fiscal year 2026 second quarter. Later on joined by Mr.

Matsuo, General Manager, Accounting Department, we'll open the floor to Q&A later. We are scheduled to end at 4:50 p.m.

Without further ado, Mr. Yamauchi, please go ahead.

Toshihiro Yamauchi

Good afternoon. I'm Yamauchi from Sumitomo Chemical.

Thank you very much for attending our conference call despite your busy schedule. I'd like to thank investors and analysts for your daily understanding and support to our management.

Thank you very much for that. Now, let me start with the briefing of our financial results for fiscal year 2026 second quarter.

Please look at slide page 4. Before explaining the details of financial results, I'd like to give a brief update on the status of profit and loss of our second quarter.

Core operating income was 144.5 billion yen. Net income attributable to owners of the parent was 82.9 billion yen, both increasing significantly compared to the same period of the previous year and exceeded the forecast announced in August.

The first half results were its second highest first half results on record. Regarding the primary factors behind the year-on-year increase in core operating income, first, ICT and mobility solutions, although shipments of display-related materials decreased with semiconductor shortages, shipments of semiconductor processing materials increased.

Agro and life solutions, although business conditions for crop protection products outside Japan have been slow to recover, shipments of crop protection products in Japan have remained steady, and profit margins for feed additives improved. Essential green materials, Petro Rabigh's financial results improved due to the situation in the Middle East, while temporary inventory valuation gains also significantly boosted core operating income.

Performance is solid, and with Sumitomo Pharma's capital increase, the D/E ratio improved significantly to 0.73 times. Consolidated financial results of the second quarter for FY 2026, sales revenue was 1 trillion 172.8 billion yen, up 77.4 billion yen year on year.

Core operating income expressing recurring earnings power was 144.5 billion yen, up 35.8 billion yen year on year. Non-recurring items not included in core operating income was a loss in total of 6.5 billion yen, worsening by 1.4 billion yen compared to the previous year.

As a result, operating income was a profit of 138.1 billion yen, up 34.4 billion yen year on year. Finance income was a loss of 16.1 billion yen, worsening of 300 million yen year on year.

Gain or loss on foreign currency transactions included in finance income or expenses was a loss of 9.4 billion yen, worsening of 3 billion yen year on year. Income tax expenses was 16.3 billion yen, compared to the same period of the previous year when tax burden was reduced due to the write-off deferred tax liabilities, tax burden increased by 19.3 billion yen.

Net income or loss attributable to non-controlling interests was a loss of 22.8 billion yen. As a result, net income attributable to owners of the parent for the second quarter was a profit of 82.9 billion yen, improvement of 43.2 billion yen year on year.

Exchange rate and naphtha price, which impact our performance, the average dollar rate during the term was 159.49 yen to a dollar, and naphtha price was 107,500 yen per kiloliter. Yen weakened and feedstock price increased year on year.

Next, sales revenue by reporting segment. Please move to page 6.

Total sales revenue was up 77.4 billion yen year on year. By segment, sales revenue increased in all segments, except essential and green materials where resale of Petro Rabigh products concluded.

As for year-on-year changes of sales revenue by factor, sales price increased by 84 billion yen, volume decreased by 64.7 billion yen, foreign exchange transaction variance of foreign subsidiary sales revenue increased by 58.1 billion yen. Next is page 7.

Total core operating income increased by 35.8 billion yen year on year. Analyzing by factor, price was +17.5 billion yen, cost -4.5 billion yen, volume variance including changes in equity in earnings of affiliates was +22.8 billion yen.

Next, performance by segment. Please move to page 8.

Agro and life solutions segment, core operating income was a profit of 20.8 billion yen, up 9.6 billion yen year on year. Income of crop protection products dropped slightly because of slow recovery in business environment outside of Japan.

Regarding the feed additives, while rising market prices have led customers to become more cautious in their purchasing decisions, the same market upturn has improved our profit margins, resulting in an increase in income. Next page.

ICT and mobility solutions segment, core operating income was a profit of 31.9 billion yen, down 1.2 billion yen year on year. For display-related products, absence of prior-year gain on the sale of a large LCD polarizing film business, decline in mobile-related shipments due to shortage of semiconductors, and decline in the selling prices of polarizing films led to decline in income.

In semiconductors-related products, though there was increase in fixed costs due to capacity expansion, shipments and a profit increased due to growing demand for semiconductors. For mobility-related products, increase in shipments of super engineering plastics led to increasing income.

Next page. Advanced medical solutions segment, core operating income was a loss of 3.7 billion yen, down 2.3 billion yen year on year.

Income dropped as a result of difference in sales mix of active pharmaceutical ingredients and intermediates and decline in profit margin at affiliated company due to the situation Middle East. Next page.

Essential green materials segment, core operating income was a profit of 62.1 billion yen, increase of 80.7 billion yen year on year. Income increased as a result of inventory valuation gains in Japan and Singapore accompanying increase in feedstock and product market prices.

Further, at Petro Rabigh, Saudi Arabia, impact of prior-year periodic plant maintenance and improvement in refining margins improved the equity method investment profit, leading to improved income. Next page.

In Sumitomo Pharma segment, core operating income was 43.6 billion yen, down 53.8 billion yen year on year. Shipments increased thanks to growth in sales of Orgovyx, a therapeutic agent for advanced prostate cancer, and Gemtesa, a treatment for overactive bladder.

On the other hand, there was the absence of the gain on the sale of the Asian business in the prior year as well as the impact of lower shipments resulting from that sale. This concludes the overview of results by segment.

On the next slide, I'll explain the consolidated statement of financial position. Total assets as of the end of September 2026 was 3 trillion 626.1 billion yen, an increase of 221 billion yen from the end of the previous fiscal year.

The main factors were temporary increase in working capital, such as trade receivables and inventories in current assets owing to the restart of the Chiba plant following the scheduled maintenance carried out in January through March 2026 and the surge in naphtha prices, and an increase in investment securities in non-current assets. Interest-bearing liabilities were 1 trillion 87.4 billion yen, a decrease of 64.1 billion yen from the end of the previous fiscal year.

Equity was 1 trillion 482.6 billion yen, an increase of 246 billion yen from the end of the previous fiscal year. This was mainly due to net income attributable to owners of the parent and Sumitomo Pharma's capital increase through a public offering.

As a result of this, equity ratio and D/E ratio significantly improved to 32.1% and 0.73 times, respectively. Next, I will explain about the consolidated statement of cash flows.

Please look at page 14. Cash flows from operating activities were an inflow of 66.6 billion yen, an increase of 8.9 billion yen year on year.

The increase was due mainly to improved profit. Cash flows from investing activities were an outflow of 84.9 billion yen, an increase of outflow of 68.2 billion yen year on year.

In the same period of the prior year, there were large inflows from items such as Sumitomo Pharma's sale of its Asian business and the sale of shares and others. As a result, free cash flows were an outflow of 18.3 billion yen, a deterioration of 59.3 billion yen compared with an inflow of 41 billion yen in the same period of the prior year.

Cash flows from financing activities were an inflow of 16 billion yen, due mainly to Sumitomo Pharma's capital increase through a public offering, an increase of inflow of 130.8 billion yen year on year. Next, I will explain our financial forecast for FY 2026.

Please turn to slide 16. Let me begin with the business environment surrounding the company.

As for economic conditions, although growth in the field of technology is firmly supporting the global economy, the outlook remains uncertain due to geopolitical risk, including tensions in the Middle East. In the business environment section, we show our main business areas and our assessment of their business environment using weather icons.

Starting from the top, for crop protection, the recovery of crop protection products outside Japan has been delayed. For feed additives, the temporary supply shortage caused by the Middle East situation has been resolved, and the current supply-demand balance has been settling down.

Although profit margin improved in the first half, the outlook for the second half and beyond remains uncertain. For displays, the mobile device market has become sluggish due to worsening procurement conditions for memory chips and other components.

Silicon semiconductors remained solid, mainly driven by AI-related areas. For petrochemicals and raw materials, we have secured enough raw materials to meet current production plans, but the impact of high raw material prices continues.

This concludes the business environment. I will now give an overview of our financial forecast.

Please turn to slide 17. This is a summary of our financial forecast for FY 2026.

We have revised the previous forecast announced in May to reflect recent business trends. Core operating income for FY 2026 is projected to be 270 billion yen, an upward revision of 55 billion yen from the previous forecast of 215 billion yen.

As a result, core operating income is expected to reach a new record high. By segment, core income in ICT and mobility solutions, essential and green materials, and Sumitomo Pharma, three segments were revised upwards.

The details will be explained in later slides. The net income attributable owners of the parent and projected to be 90 billion yen, upward revision of 20 billion yen from the previous forecast of 70 billion yen.

The year-end dividend is revised upward to 9 yen, with a 1 yen increase. As a result, annual dividend is projected to be 17 yen, 1 yen higher than last projected.

Please go to page 18. For FY 2026, we forecast the following: sales revenue is 2 trillion 490 billion yen, up 130 billion yen from the previous forecast; core operating income of 270 billion yen, as mentioned in the previous slide; net income attributable to owners of the parent being 90 billion yen.

As for our exchange rate and naphtha price assumptions, we assume an exchange rate of 150 yen to the dollar for the second half, or 157 yen for the full year, and 99,000 yen per kiloliter for the full year. Next, I will explain slide 19, sales revenue and core operating income by reporting segment.

Looking at the full-year forecast by segment, for agro and life solutions, although profit margin for methionine has improved, the recovery in sales of crop protection products outside Japan has been delayed, we have left the previous forecast unchanged. For ICT and mobility solutions, we expect an increase from 55 billion to 60 billion due to increased shipments of semiconductor processing materials.

For essential and green materials, we expect a large increase in profit from 20 billion to 75 billion yen due to the improvement in Petro Rabigh profit and loss that has been impacted by the Middle East situation and temporary inventory valuation gains. For Sumitomo Pharma, we expect an increase in profit from 94 billion to 108 billion yen due to strong sales of Gemtesa.

Please note that the lower profit in the others segment compared with the previous forecast is because we have factored in certain levels of risks. This concludes our explanation of the financial results and forecasts.

We will now like to open to the floor and receive your questions.

Operator

Thank you very much. Now, we'd like to receive your questions.

Now, we will have the first question. From Morgan Stanley MUFG Securities, Mr.

Watabe.

Takato Watabe

Thank you for presentation. My name is Watabe.

About agro and life, I had a question. First, in the second quarter, compared to the forecast, it is lower, what is the background for that?

The second half, there's upward revision. Overseas crop protection chemicals were slow in recovering, but what's the background?

What's the situation by region about agro? Methionine market price seems to be fluctuating, could you also explain that?

Toshihiro Yamauchi

Yes, thank you for your question. Overseas crop protection chemicals, demand recovery is delayed in Middle and South America.

Previous year, compared to 2025, 2026, we expect a recovery in Latin America and we expected recovery of the market, but there's a delay in recovery. One factor is the credit uncertainties in the farmers, which is not yet been resolved.

This year, Super El Niño is being mentioned. This impact seems to be seen somewhat in Brazil.

It's not yet at a level that would affect the cultivation, but the farmers are refraining from purchasing, there is a delay in recovery of demand. By region, North America, it's not that it is worsening, but there is a shift of shipments from the first half to the second half.

In India, in the first quarter, because of El Niño, monsoon arrival is delayed, but finally, it is starting to rain. The volume of rain seems to be low.

Compared to the forecast, there is underachievement. In India, second half, the Indiflin was launched last year, we hope we can recover through these products in the second half.

Methionine, in the first half, there were some confusions and the market price remained high. It is stabilizing slightly now.

For the second half, the assumption is that the sales price in the forecast is expected. The underachievement in the first half is the delay in the Central and South America and impact of monsoon in India, which led to underachievement, and it seems that there's an increase in the second half because there is a shift, and in addition, methionine is expected to be better than the original forecast.

For the forecast in May, we didn't expect any positive figures from methionine, but in the current forecast, we made the upward revision of income. In general, for the crop protection chemicals, compared to May, we have incorporated some downward revision.

Takato Watabe

I think you mentioned that you expect overachievement in the second half, but, yes, your explanation was clear. Thank you.

Operator

Thank you very much, Mr. Watabe.

We'd like to take the next question. From Mizuho Securities, Mr.

Yamada, please go ahead.

Mikiya Yamada

This is Yamada from Mizuho Securities speaking. Thank you.

I have one question regarding ICT and mobility solutions. The display, the information appliances is not doing well.

Usually in this section, there's a revision, but the first half of 13.9 billion and the second half revised is 28.1 billion core operating income. It seems that there's no difference between the first and second half.

Is that because, or correct to think that that is because the semiconductor is going to grow in the second half? If it is a semiconductor, what is strongly performing within that?

Regarding the resist sales situation, are there any changes the new product sales? Can you share that with us?

Toshihiro Yamauchi

Thank you very much for your question. FY 2026, the difference between the first and second half is your question is how I understood it.

Regarding the display, as usually is, there's a difference between the first and second half. Compared to the first half, the second half, due to the seasonality, there's a decline in profit.

That is our projection. As for the semiconductors, compared to the first half, the second half is going to further grow.

That is our outlook. Therefore, here, the usually occurring difference between the first and second half is becoming slightly milder.

Mikiya Yamada

Is there a certain product that is contributing to this?

Toshihiro Yamauchi

Semiconductor-related product markets is strongly performing. In our case, at this point, is the front-end resist and semiconductor chemicals for us, and these products are performing well for us.

Super engineering plastics was performing well as well.

Mikiya Yamada

How much of a positive impact they have for the volume increase? Is this situation going to continue in the second half?

Toshihiro Yamauchi

For the super engineering plastics, I did explain in the first quarter, the Chinese economic stimulus measures, due to that, towards the electronic components, the shipment is strong, and that market price is continuing.

Mikiya Yamada

Understood. Thank you very much.

I have high expectations.

Toshihiro Yamauchi

Thank you.

Operator

Thank you very much, Mr. Yamada.

The next question from SMBC Nikko Securities, Mr. Miyamoto.

Go Miyamoto

Thank you. I'm Miyamoto from SMBC Nikko Securities.

I have a question about essential green materials. First, compared to the previous forecast in the first half, it is quite upward by about 20 billion, and towards the second half, it is about 13 billion.

Petro Rabigh net loss, the level in July-September was very high, as high as the previous quarter. I don't expect such a large loss, but what are the assumptions for those figures?

Naphtha shortage in Singapore is having an impact, could you tell me the factor for your forecast for essential green materials? Comparison with the first half, for essential green materials, what was good about the first half?

Toshihiro Yamauchi

As of August, in the first half, inventory valuation gains was posted, and we thought with the stabilization situation in the Middle East, the second half, we start with losses, that was our forecast. Naphtha remains at a high price, the valuation loss of the first quarter still remains.

Another point, in the forecast of August, we expected some gains from sales of businesses, but actually in the first half, some was reflected in essentials. That was the situation in the first half.

Throughout the year, second half looks weaker. First, for Petro Rabigh, results up to September is already announced, and in our case, the third quarter includes those assumptions.

From October to December, the refining margin at the moment is advancing quite steadily, but there are also risk factors. For the fourth quarter, we are not assuming positive factors.

Naphtha price, currently, is more than 100,000 yen, but towards the end of the year, we expect 90,000 yen in the second half. For the inventory valuation loss or gains, we expect there'll be some recovery in the second half.

Go Miyamoto

What is the situation Singapore?

Toshihiro Yamauchi

In Singapore, there's not much change. After the force majeure declaration, it is still not being lifted.

Naphtha price remains at a high level. Naphtha is becoming easier to procure, but we have to consult with the customers in conducting these operations.

The level of the operation remains at a similar level as that of the first quarter.

Go Miyamoto

Thank you very much.

Toshihiro Yamauchi

For naphtha price, the assumption on three months ago was 104,000, the result was 107,000, it's not that difference. Singapore operations in Singapore, the spot price for naphtha and crude oil would directly impact, maybe that was the factor of the impact.

Go Miyamoto

For the gains of selling the business, is that at a two-digit level?

Toshihiro Yamauchi

Yes, first, for naphtha, in the second quarter, we expected higher levels, but the inventory valuation loss is the prices as of the end of the term. We assumed some drop at the end of the second quarter.

The sales gains, there's nothing that we can talk too much. We expected about 5 billion yen, but it is more than that.

Under summary, the figures excluding those gains are included, if you calculate from that, I think you can have an idea of the amount.

Go Miyamoto

Yes, understand. Thank you very much.

Operator

Mr. Miyamoto, thank you very much.

We'd like to take the next question from Daiwa Securities, Mr. Umebayashi, please go ahead.

Hidemitsu Umebayashi

Thank you. This is Umebayashi from Daiwa Securities.

My question may be slightly in detail. The core operating income, the other adjusted areas, the second half was about -30 billion, and in your previous explanation, you said that you are reflecting some risks to a certain level.

Is it okay to simply look at it as a buffer, or is there some specific item for this is what I would like to know. Similar to that, the core operating income and operating income, and between that, the first half was -6.5, and the second half is about 49 billion after all the calculations.

The reason why this negative number is going to become enlarged in the second half is I'd like to know the reason.

Toshihiro Yamauchi

Thank you very much for your question. For the other risk factors, money amount-wise, it's about 10 billion yen that is incorporated.

At the start of the fiscal year or the quarter, which is May, we did reflect the risks of the Middle East situation, and as a result, a similar amount is incorporated. It's not that specific risks are existing, the Middle East situation is still uncertain, we have reflected that.

Also the inventory valuation positive number, the naphtha, we're looking at 90,000, and we assume that the valuation is going to remain to the second half, but there are areas that is difficult to have a clear visibility, including those type of risks as well, we are incorporating it as risk factors.

Hidemitsu Umebayashi

Thank you very much. The non-recurring items?

Toshihiro Yamauchi

For non-recurring items, the business situation is still uncertain. Last fiscal year, there was about nine non-recurring items, about 55 billion yen, that was actually reflecting such as business structuring, restructuring expenses and others.

We are at this point, incorporating some risk factors. Same as the last fiscal year, towards the second half, it becomes more prominent, so that is why we're reflecting these within the second half numbers as well.

Hidemitsu Umebayashi

Thank you very much. Related to Singapore, is there a possibility that something may come up?

Toshihiro Yamauchi

Apologies, I cannot speak about the content of that, I would like to refrain from commenting.

Hidemitsu Umebayashi

Understood. That is all.

Thank you.

Toshihiro Yamauchi

Thank you.

Operator

Thank you very much, Mr. Umebayashi.

The next question is from BofA Securities, Mr. Enomoto.

Takashi Enomoto

Thank you. My name is Enomoto from BofA.

About ICT and mobility, photoresist or semiconductor chemicals, semiconductor materials, what is the situation in the price revision? The competitors are talking about revising the price, and I think that would affect your company as well.

Toshihiro Yamauchi

Yes, thank you for the question. Mainly, with a higher feedstock prices, you're asking about price revision in a certain company?

Yes, in our case also, we are consulting with the customers and revised to an appropriate price level.

Takashi Enomoto

If possible, could you tell me what would be the scale, and with higher feedstock prices, there's price revision, but what is the assumption for the spread? I think with the strong demand, you can enjoy some spread.

Toshihiro Yamauchi

The scale of the amount, I have to refrain from mentioning that. Improvement of spread, also that is our sales strategy, it's quite difficult to talk about it.

In terms of costs, not only feedstock price, but fixed cost is also increasing, including labor cost. Including that, we are having discussions about a price revision.

Takashi Enomoto

Understand. Thank you very much.

Toshihiro Yamauchi

Thank you.

Operator

Mr. Enomoto, thank you very much.

We'd like to take the next question from Nomura Securities, Mr. Okazaki, please go ahead.

Shigeki Okazaki

This is Okazaki from Nomura Securities. Thank you very much.

Against the first half, the second half, you have announced an increase in dividend. I would like to know the way of thinking behind this.

You're aiming for a 24 yen per share dividend, I know that. This time, Sumitomo Pharma or ICT performed strongly, but on the other hand, maybe it's temporarily, but Rabigh or methionine market price is improving, and that is contributing to the improvement of profit.

Moving forward, you would like to avoid from decreasing the dividend. What is the direction, and I would like to know the thoughts behind the dividends.

That is all.

Toshihiro Yamauchi

Thank you very much for your question. Regarding the dividends, well, it may become a qualitative type of explanation.

However, this fiscal year's performance and also from next fiscal year onwards performance outlook, we took a comprehensive look at those and decided on it. Regarding this fiscal year, the first half business performance was quite strong.

Also regarding the second half, there are some uncertainties, therefore, we do consider certain of risk factors. Considering all that, we have decided on the amount of dividend.

In that sense, as you pointed out, Mr. Okazaki, the past high of 24 yen, record past record high 24 yen, of course as a company we like to aim to do that.

However, the uncertainties in the future and some outlook for next fiscal year onwards, if it becomes brighter, we would like to decide upon the dividend once again.

Shigeki Okazaki

Understood very well. That's all.

Thank you very much.

Toshihiro Yamauchi

Thank you.

Operator

Thank you very much, Mr. Okazaki.

Let me move to the next question. From UBS Securities, Ohmuda-san.

Shunta Omura

Thank you. I am Omura from UBS Securities.

I have a question about the cash flow on page 14. Investment cash flows plan for this year, 150 billion, and seems that the progress is slightly higher.

In the first half, cash flows from investing activities, about the content, and the full year plan, are there any changes in the plan?

Toshihiro Yamauchi

Thank you for the question. Cash flows annual forecast, the revised figures are not being disclosed.

Performance itself is good, positive factors on cash flow do exist. However, on the other hand, we're seeing improvement in performance, there's improvement of equity method investment gains, and also inventory valuation gains, not related to cash flows, I think that should also be taken into consideration.

That is all.

Shunta Omura

Thank you very much. For cash flows from investing activities, any major item in the first half?

From second half onwards, compared to the initial 150 billion yen, is there anything that would go beyond that level? Maybe inflation maybe related?

Toshihiro Yamauchi

The first half cash flows from investing activities, partially, not ordinary capital investment, M&A, but from accounting reasons, like surplus funds, even if that is deposited on banks for more than three months, that would be deducted as investment activities cash flow. In the first half, these items are included.

Compared to the actual situation, cash flows from investing activities may look bigger. This is a one-time case.

It would return towards the end of the year. In the second half, no major changes from what we assumed in the beginning of the year.

Shunta Omura

Thank you very much.

Toshihiro Yamauchi

Thank you.

Operator

Mr. Omura, thank you very much.

We'd like to take the next question from Morgan Stanley MUFG Securities, Mr. Watabe, please go ahead.

Takato Watabe

Sorry, for the second round a question. I wanted to ask about the dividends as well, but that was already asked.

Petro Rabigh, Rabigh's third quarter financial results, within there, there were geopolitical disruptions, such wording was used. Even though the refinery margin was good, the profit was not so good.

Is that because of this reason, or the Strait of Hormuz is closed right now, but the Red Sea side is in operation? Because of that, is there some confusion regarding the Rabigh's supply?

Is there any issues? Can you explain about that?

Toshihiro Yamauchi

Thank you very much for your question. Regarding Petro Rabigh, at the Middle East, there are various media reporting.

However, from the company side will be the financial results announcement. Information more than that, it's difficult to share that with you in a public situation.

At this point, we did not think that there is a large impact in the shipment. For the July situation, there was a slight impact for the operation, but our understanding is that that was the reason.

Takato Watabe

There was an impact on the operation. What was the reason for that?

Toshihiro Yamauchi

The Middle East situation, I cannot share details with you. Because right now in the Middle East, various things are occurring, and of course, we understand that there are various risks there as well.

Partially, there was some impact to the operation that became recognized. However, if you look at the numbers, you will know that it was not a large impact.

I would like you to understand it in that way.

Takato Watabe

Understood. Thank you very much.

Operator

Thank you very much, Mr. Watabe.

We still have a few minutes before the scheduled time to close. We can receive one more question.

Any other questions? If you have any questions, please let us know.

Mr. Yamada from Mizuho Securities.

Mikiya Yamada

Thank you. I'm Yamada from Mizuho Securities.

I have one question. This may be a very detailed question.

Today, the final contract of succession of Takeda was announced today, and in Q3, from Q3, this business is going to be consolidated. For advanced medical solutions, this business would be included.

In the first half, there was a slight underachievement, and of course, there's a final agreement in July, I think it is included in August. Advanced medicals now is no change.

Because of this succession in the second half, do you expect a shift to surplus? Towards the next fiscal year, can we expect improvement, or would this be included under others?

Could you tell me that?

Toshihiro Yamauchi

Yes, thank you for waiting. Yes, as you mentioned, in the second half, that will be included in the ADM segment.

For the first half and second half, in the second half, there's a concentration of profit. This is one of the factors, but rather under pharma solutions, shipment timing is one factor.

It is more of a second half business, so that is the situation.

Mikiya Yamada

Understood. Last year, I think there was a loss 1.4 billion in the first half and positive 2.4 billion in the second half.

A pattern like last year, and also former Takeda's business will also be making contributions, is that correct?

Toshihiro Yamauchi

Yes, your understanding is correct.

Mikiya Yamada

Thank you very much.

Toshihiro Yamauchi

Thank you. Mr.

Operator

Yamada, thank you very much. It has become close to the schedule ending time, we'd like to take the last question as the last question.

From Daiwa Securities, Mr. Umebayashi, please go ahead.

Hidemitsu Umebayashi

This is Umebayashi from Daiwa Securities. Regarding the methionine, I would like to ask some confirmation questions.

The second half, the price is in line with what you have expected is what you said. To begin with, this first half, it was slightly high, that is because there was a supply restrictions or constraints of your competitor, and that has become resolved, the price has come back to the usual price?

Compared to the start of the fiscal year plan, it seems that slightly the raw material prices is changing, the way of thinking towards the margin, can it remain as the same as the start of the fiscal year? I just wanted to confirm that.

Toshihiro Yamauchi

Thank you very much for your question. Regarding methionine, in the first half, as you saw, the confusion of the supply and demand has started to settle down.

However, the raw material prices has remained high. For us, we would like to thoroughly discuss with our customers so that we'll be able to pass on the cost.

That's how we will think about it, I'd like you to understand in that way as well.

Hidemitsu Umebayashi

Thank you.

Toshihiro Yamauchi

Thank you.

Operator

Thank you very much, Mr. Umebayashi.

This concludes today's conference call. Thank you very much for your participation.